Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity

Gobec, Stanislav; Sollner-Dolenc, Marija; Urleb, U.; Wraber, Branka; Simčič, Saša; Filipič, Metka

doi:10.1016/j.farmac.2004.01.003

Cited by 7 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TT MAP formulated with alum had a biased T H 2 response whereas TT MAP formulated with MDP shows a balanced T H 1/T H 2 response. Previous experiments on MDP has reported on the elicitation of cytokines in vitro mediated by chemical analogues of MDP (Gobec et al, 2004), where some resulted in type I cytokine secretion but others resulted in more balanced cytokine profi les (Moschos et al, 2005). Vaccines formulated with MDP when combined with liposomes may enhance higher cell mediated immune responses.…”

Section: Discussionmentioning

confidence: 99%

Effect of muramyl dipeptide and alum adjuvants on immunization with Filarial multi antigen peptide vaccine in mice model

et al. 2016

View full text Add to dashboard Cite

SummaryFilarial thioredoxin and transglutaminase are enzymes that are secreted throughout the lifecycle of the parasites which are mandatory for the survival of the parasite. They are reported to be promising vaccine candidates, yet the limitation factors of these proteins to be developed as vaccines is their homology they share with the host proteins. Hence immunodominant epitopes from these proteins were constructed as peptides and immunised in mice model with Muramyl dipeptide (MDP) as adjuvant. Immunodominant epitopic portions from Filarial thioredoxin and transglutaminase which are non-homologous with host proteins were constructed as Multi Antigen Peptide (MAP) and assembled in an inert lysine core. The synthesised MAP was immunised with MDP as adjuvant in Balb/c mice model, humoral and cellular immune response were studied. Antibody titre levels for TT MAP with MDP was in par with alum as adjuvant in mice models. T cell responses of TT MAP with MDP showed a balanced T H 1/T H 2 response. The T H 1 cytokines namely IL-2 and IFN-ɤ were also higher in TT MAP immunised groups with MDP as adjuvant whereas alum immunised groups was T H 2 biased. TT MAP admixed with MDP as adjuvant proves to be safe in mice model. Further vaccination studies are underway in permissive animal models to determine the role of TT MAP with MDP as adjuvant in protective immunity against W. bancrofti and B. malayi infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of muramyl dipeptide and alum adjuvants on immunization with Filarial multi antigen peptide vaccine in mice model

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the next step, the PBMC cultures were incubated for 40 h in a CO 2 incubator at T = 378C, in 5% CO 2 atmosphere and 95% humidity. After the incubation, the concentration of the produced cytokines IL-2, IFN-g, IL-4, IL-10 and IL-17 in the culture supernatants was measured with commercially available ELISA kits [20,21].…”

Section: Figurementioning

confidence: 99%

Submerged cultivation of Ganoderma lucidum and the effects of its polysaccharides on the production of human cytokines TNF-α, IL-12, IFN-γ, IL-2, IL-4, IL-10 and IL-17

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Several lipophilic variants of MDP were evaluated for efficacy against various viral infections including CMV, influenza and Punta Toro virus in experimental animals [63] and against HIV in humans [64]. Different molecular variants of MDP were shown to strongly promote Th-1 responses, whereas others promoted Th-2 responses or both Th-1 and Th-2 responses [65].…”

Section: Other Immunomodulatorsmentioning

confidence: 99%

New Strategies for Immune-Mediated Anti-Viral Drug and Vaccine Development

Chen¹,

Ron²

2006

CPD

View full text Add to dashboard Cite

Substantial progress in the development of new anti-viral drugs has taken place in recent years. Most of these new drugs belong to three groups of compounds, nucleoside analogs, thymidine kinase-dependent nucleotide analogs and specific viral enzyme inhibitors. Although these drugs revolutionized the treatment of several viral diseases, the involvement of the immune system is crucial for complete recovery and prevention of re-infection. New advances in the understanding of immune regulation mechanisms, mainly the role of cytokines, led to the development of several new immunologically-based anti-viral drugs and treatments. The most studied group of immunomodulators is the cytokines, some of which were shown to act as potent stimulators of immune responses. Other, non-cytokine immune modulators have also been successfully employed in both humans and experimental animals as anti-viral drugs of which several are currently in clinical trials. Advances in genetic engineering and transgenic mouse technologies facilitated the production of humanized as well as authentic human anti-viral monoclonal antibodies. Some of these antibodies proved to be clinically efficacious and are commercially produced as anti-viral drugs. As is often the case in anti-viral treatments, a combination of conventional and an immune-mediated anti-viral drugs or a combination therapy involving immunomodulators, therapeutic vaccines, immune intervention and even gene therapy might prove most efficacious as a treatment for a particular virus. Most of the advances made in anti-viral treatments have also been applied to the development of new vaccines. Some of the classical attenuated viruses are being replaced by recombinant attenuated viruses. Recombinant viral vaccines containing genes encoding other viral antigens and/or cytokines are being tested as new vaccines. Several chimeric viral vaccines have proven efficacious in experimental animals and are now in different phases of clinical trials. This review will encompass the major new developments in this field, including some that have not yet been subjected to human trials.

show abstract

Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity

Cited by 7 publications

References 40 publications

Effect of muramyl dipeptide and alum adjuvants on immunization with Filarial multi antigen peptide vaccine in mice model

Effect of muramyl dipeptide and alum adjuvants on immunization with Filarial multi antigen peptide vaccine in mice model

Submerged cultivation of Ganoderma lucidum and the effects of its polysaccharides on the production of human cytokines TNF-α, IL-12, IFN-γ, IL-2, IL-4, IL-10 and IL-17

New Strategies for Immune-Mediated Anti-Viral Drug and Vaccine Development

Contact Info

Product

Resources

About